| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, T-Cell, Cutaneous | 36 | 2024 | 210 | 5.230 |
Why?
|
| Skin | 73 | 2022 | 4499 | 3.520 |
Why?
|
| Immunologic Memory | 22 | 2022 | 1377 | 3.400 |
Why?
|
| Mycosis Fungoides | 14 | 2024 | 169 | 3.090 |
Why?
|
| T-Lymphocytes | 55 | 2022 | 10263 | 2.890 |
Why?
|
| Skin Neoplasms | 46 | 2024 | 5860 | 2.140 |
Why?
|
| T-Lymphocyte Subsets | 16 | 2022 | 1814 | 2.130 |
Why?
|
| Interleukin-1 | 35 | 2005 | 1251 | 2.120 |
Why?
|
| Keratinocytes | 30 | 2015 | 876 | 1.840 |
Why?
|
| Epidermis | 27 | 2012 | 539 | 1.680 |
Why?
|
| Skin Diseases | 16 | 2022 | 1084 | 1.680 |
Why?
|
| Sezary Syndrome | 6 | 2024 | 80 | 1.400 |
Why?
|
| Vaccinia virus | 10 | 2019 | 328 | 1.370 |
Why?
|
| CD8-Positive T-Lymphocytes | 16 | 2023 | 4652 | 1.230 |
Why?
|
| E-Selectin | 18 | 2012 | 576 | 1.220 |
Why?
|
| Membrane Glycoproteins | 20 | 2014 | 3702 | 1.170 |
Why?
|
| Dermatitis, Contact | 11 | 2017 | 134 | 1.170 |
Why?
|
| Psoriasis | 16 | 2017 | 925 | 1.140 |
Why?
|
| Sewage | 8 | 2008 | 44 | 1.050 |
Why?
|
| Langerhans Cells | 7 | 2013 | 169 | 0.930 |
Why?
|
| Receptors, CCR4 | 8 | 2014 | 77 | 0.910 |
Why?
|
| Dermatitis | 9 | 2016 | 203 | 0.900 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 5 | 2019 | 354 | 0.860 |
Why?
|
| Waste Disposal, Fluid | 6 | 2008 | 34 | 0.820 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 19 | 2015 | 897 | 0.800 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2022 | 97 | 0.750 |
Why?
|
| Genes, T-Cell Receptor beta | 3 | 2018 | 70 | 0.750 |
Why?
|
| T-Lymphocytes, Regulatory | 13 | 2015 | 3114 | 0.740 |
Why?
|
| Interleukin-1alpha | 2 | 2020 | 88 | 0.740 |
Why?
|
| Receptors, Lymphocyte Homing | 9 | 2018 | 141 | 0.730 |
Why?
|
| Receptors, Interleukin-1 | 12 | 2005 | 260 | 0.710 |
Why?
|
| Antigens, Neoplasm | 20 | 2014 | 1998 | 0.660 |
Why?
|
| Interleukin-17 | 5 | 2020 | 923 | 0.650 |
Why?
|
| Lymphoma, T-Cell | 5 | 2023 | 308 | 0.640 |
Why?
|
| Dermis | 3 | 2017 | 203 | 0.620 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2017 | 2571 | 0.610 |
Why?
|
| CD4-Positive T-Lymphocytes | 12 | 2022 | 4410 | 0.590 |
Why?
|
| Adaptive Immunity | 2 | 2020 | 734 | 0.580 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2015 | 1802 | 0.580 |
Why?
|
| Immunity, Cellular | 8 | 2010 | 1560 | 0.580 |
Why?
|
| Immunologic Surveillance | 3 | 2006 | 92 | 0.570 |
Why?
|
| Th17 Cells | 3 | 2020 | 790 | 0.570 |
Why?
|
| Dermatitis, Allergic Contact | 2 | 2015 | 112 | 0.560 |
Why?
|
| Mice | 94 | 2022 | 81898 | 0.550 |
Why?
|
| Dermatology | 6 | 2018 | 905 | 0.540 |
Why?
|
| Inflammation | 19 | 2019 | 10863 | 0.540 |
Why?
|
| Interleukins | 9 | 2017 | 796 | 0.520 |
Why?
|
| Melanoma | 10 | 2022 | 5702 | 0.520 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2017 | 812 | 0.510 |
Why?
|
| Lymphocyte Activation | 22 | 2014 | 5502 | 0.510 |
Why?
|
| Animals | 118 | 2022 | 168939 | 0.500 |
Why?
|
| Cells, Cultured | 41 | 2020 | 18986 | 0.500 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2017 | 393 | 0.490 |
Why?
|
| Candida albicans | 2 | 2017 | 377 | 0.490 |
Why?
|
| Smallpox Vaccine | 2 | 2013 | 77 | 0.480 |
Why?
|
| Candidiasis | 1 | 2017 | 372 | 0.480 |
Why?
|
| Cell Movement | 18 | 2017 | 5204 | 0.480 |
Why?
|
| Gene Expression Profiling | 9 | 2021 | 9528 | 0.470 |
Why?
|
| Poxviridae | 2 | 2015 | 37 | 0.470 |
Why?
|
| Vaccinia | 4 | 2017 | 71 | 0.460 |
Why?
|
| Vaccines | 1 | 2023 | 842 | 0.460 |
Why?
|
| Neutrophil Infiltration | 1 | 2017 | 392 | 0.450 |
Why?
|
| Dendritic Cells | 12 | 2020 | 2747 | 0.450 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 1026 | 0.450 |
Why?
|
| Smallpox | 1 | 2013 | 43 | 0.440 |
Why?
|
| Antibodies, Monoclonal | 13 | 2020 | 9244 | 0.430 |
Why?
|
| Keratins | 13 | 2004 | 499 | 0.430 |
Why?
|
| Soil | 4 | 2008 | 119 | 0.430 |
Why?
|
| Janus Kinases | 1 | 2014 | 253 | 0.420 |
Why?
|
| Interleukin-9 | 2 | 2014 | 62 | 0.420 |
Why?
|
| Mice, Transgenic | 27 | 2016 | 9546 | 0.420 |
Why?
|
| Allergy and Immunology | 1 | 2014 | 170 | 0.420 |
Why?
|
| Viral Vaccines | 2 | 2010 | 596 | 0.410 |
Why?
|
| Water Pollutants, Chemical | 5 | 2009 | 356 | 0.410 |
Why?
|
| Cytokines | 22 | 2014 | 7438 | 0.410 |
Why?
|
| Ultraviolet Rays | 7 | 2006 | 1100 | 0.410 |
Why?
|
| Flame Retardants | 3 | 2009 | 97 | 0.410 |
Why?
|
| Immunity, Innate | 9 | 2019 | 3079 | 0.410 |
Why?
|
| P-Selectin | 12 | 2012 | 598 | 0.410 |
Why?
|
| Cell Separation | 7 | 2013 | 1718 | 0.400 |
Why?
|
| Refuse Disposal | 4 | 2008 | 31 | 0.400 |
Why?
|
| Antigens | 4 | 2012 | 1442 | 0.400 |
Why?
|
| Alopecia Areata | 1 | 2014 | 130 | 0.390 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 58 | 0.390 |
Why?
|
| Dermatitis, Atopic | 7 | 2021 | 734 | 0.390 |
Why?
|
| Humans | 186 | 2024 | 766812 | 0.380 |
Why?
|
| Interleukin-7 | 2 | 2005 | 146 | 0.380 |
Why?
|
| Cell Adhesion Molecules | 8 | 2005 | 1612 | 0.380 |
Why?
|
| Neutrophils | 5 | 2017 | 3782 | 0.380 |
Why?
|
| Flow Cytometry | 21 | 2015 | 5890 | 0.380 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2022 | 3667 | 0.370 |
Why?
|
| Aminoquinolines | 3 | 2009 | 105 | 0.370 |
Why?
|
| Contraceptive Agents | 1 | 2012 | 147 | 0.370 |
Why?
|
| Immunity | 2 | 2015 | 1002 | 0.350 |
Why?
|
| Antibody Formation | 5 | 2005 | 1392 | 0.350 |
Why?
|
| Pesticides | 3 | 2008 | 297 | 0.350 |
Why?
|
| Clone Cells | 9 | 2022 | 1670 | 0.350 |
Why?
|
| Papilloma | 3 | 2003 | 143 | 0.350 |
Why?
|
| Mice, SCID | 8 | 2020 | 2626 | 0.350 |
Why?
|
| Integrins | 6 | 1995 | 839 | 0.340 |
Why?
|
| Antigens, CD | 11 | 2015 | 4033 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 23 | 2022 | 22351 | 0.340 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 3942 | 0.330 |
Why?
|
| Interleukin-2 | 13 | 2015 | 1895 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2018 | 8623 | 0.330 |
Why?
|
| Growth Substances | 8 | 1996 | 759 | 0.330 |
Why?
|
| Graft vs Host Disease | 3 | 2020 | 3079 | 0.330 |
Why?
|
| Immune System | 6 | 2015 | 800 | 0.330 |
Why?
|
| Mice, Knockout | 14 | 2020 | 14473 | 0.330 |
Why?
|
| Models, Immunological | 6 | 2015 | 517 | 0.330 |
Why?
|
| Receptors, Chemokine | 4 | 2006 | 652 | 0.320 |
Why?
|
| Biological Factors | 5 | 1990 | 155 | 0.320 |
Why?
|
| Interleukin-15 | 2 | 2006 | 186 | 0.310 |
Why?
|
| Interleukin-16 | 3 | 2014 | 34 | 0.310 |
Why?
|
| Lipid Metabolism | 2 | 2017 | 1895 | 0.310 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 8 | 2014 | 975 | 0.300 |
Why?
|
| Th2 Cells | 4 | 2013 | 1077 | 0.300 |
Why?
|
| Receptors, Very Late Antigen | 3 | 1993 | 74 | 0.300 |
Why?
|
| Disinfectants | 2 | 2007 | 131 | 0.300 |
Why?
|
| Gene Expression | 13 | 2023 | 7585 | 0.290 |
Why?
|
| Neoplasm Proteins | 5 | 2017 | 3600 | 0.290 |
Why?
|
| Interferon-gamma | 7 | 2020 | 3157 | 0.290 |
Why?
|
| Monocytes | 5 | 2005 | 2599 | 0.280 |
Why?
|
| Caspase 1 | 2 | 2006 | 227 | 0.280 |
Why?
|
| Cell Proliferation | 8 | 2016 | 10451 | 0.280 |
Why?
|
| Neoplasms | 4 | 2020 | 22350 | 0.280 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2020 | 292 | 0.270 |
Why?
|
| Adoptive Transfer | 2 | 2013 | 828 | 0.270 |
Why?
|
| Polycyclic Compounds | 1 | 2006 | 28 | 0.270 |
Why?
|
| Interleukin-18 | 2 | 2006 | 251 | 0.270 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2020 | 1105 | 0.270 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2022 | 527 | 0.260 |
Why?
|
| Colony-Stimulating Factors | 5 | 1990 | 218 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2009 | 4050 | 0.260 |
Why?
|
| Lymph Nodes | 7 | 2018 | 3468 | 0.260 |
Why?
|
| Fibroblasts | 8 | 2006 | 4166 | 0.250 |
Why?
|
| Interleukin-12 | 3 | 2006 | 581 | 0.250 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2012 | 3738 | 0.250 |
Why?
|
| Tumor Escape | 1 | 2008 | 371 | 0.250 |
Why?
|
| Sialoglycoproteins | 4 | 2005 | 316 | 0.250 |
Why?
|
| Estradiol | 1 | 2012 | 1947 | 0.240 |
Why?
|
| Tetradecanoylphorbol Acetate | 7 | 2003 | 826 | 0.240 |
Why?
|
| Vitamin A | 2 | 2007 | 611 | 0.240 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2006 | 588 | 0.240 |
Why?
|
| Antigen-Presenting Cells | 5 | 2020 | 960 | 0.240 |
Why?
|
| Immune Tolerance | 9 | 2009 | 2328 | 0.240 |
Why?
|
| Up-Regulation | 7 | 2020 | 4143 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2001 | 1405 | 0.230 |
Why?
|
| Epitopes | 1 | 2011 | 2526 | 0.230 |
Why?
|
| Keratin-14 | 6 | 2009 | 57 | 0.230 |
Why?
|
| Mice, Inbred NOD | 6 | 2020 | 1836 | 0.230 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 5 | 2017 | 299 | 0.230 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2024 | 53 | 0.220 |
Why?
|
| RNA, Messenger | 19 | 2015 | 12795 | 0.220 |
Why?
|
| Antineoplastic Agents | 10 | 2016 | 13644 | 0.220 |
Why?
|
| Cellulitis | 2 | 2016 | 206 | 0.220 |
Why?
|
| Interferon-alpha | 2 | 2010 | 910 | 0.220 |
Why?
|
| Immunity, Active | 1 | 2003 | 58 | 0.220 |
Why?
|
| L-Selectin | 4 | 2010 | 212 | 0.220 |
Why?
|
| Forkhead Transcription Factors | 5 | 2010 | 1627 | 0.220 |
Why?
|
| Autoantigens | 2 | 2005 | 890 | 0.220 |
Why?
|
| Platelet Membrane Glycoproteins | 2 | 1994 | 282 | 0.220 |
Why?
|
| Receptors, CXCR4 | 3 | 2021 | 729 | 0.210 |
Why?
|
| Photopheresis | 1 | 2003 | 35 | 0.210 |
Why?
|
| Hair Follicle | 3 | 2016 | 219 | 0.210 |
Why?
|
| Cell Adhesion | 12 | 2007 | 3093 | 0.210 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2004 | 190 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 2 | 2003 | 996 | 0.210 |
Why?
|
| Soil Pollutants | 3 | 2007 | 77 | 0.200 |
Why?
|
| Monitoring, Immunologic | 3 | 2018 | 99 | 0.200 |
Why?
|
| Immunocompetence | 2 | 2017 | 138 | 0.200 |
Why?
|
| Cholecalciferol | 1 | 2007 | 550 | 0.200 |
Why?
|
| Burns | 10 | 1996 | 1902 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5753 | 0.200 |
Why?
|
| Cell Division | 13 | 2016 | 4473 | 0.190 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 434 | 0.190 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2023 | 125 | 0.190 |
Why?
|
| Receptors, CCR7 | 2 | 2013 | 105 | 0.190 |
Why?
|
| Exotoxins | 1 | 2022 | 123 | 0.190 |
Why?
|
| Endothelium, Vascular | 8 | 2005 | 4424 | 0.190 |
Why?
|
| Mucin-1 | 2 | 2017 | 536 | 0.190 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 11218 | 0.190 |
Why?
|
| Polychlorinated Biphenyls | 4 | 2007 | 235 | 0.190 |
Why?
|
| Disease Models, Animal | 13 | 2020 | 18329 | 0.190 |
Why?
|
| Phenotype | 15 | 2019 | 16722 | 0.190 |
Why?
|
| Immunization | 3 | 2015 | 1218 | 0.180 |
Why?
|
| Female | 60 | 2024 | 396532 | 0.180 |
Why?
|
| Ligands | 6 | 2010 | 3274 | 0.180 |
Why?
|
| Intercellular Adhesion Molecule-1 | 6 | 2007 | 1131 | 0.180 |
Why?
|
| Neoplasm Transplantation | 4 | 2018 | 2012 | 0.180 |
Why?
|
| Interleukin-13 | 2 | 2013 | 391 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2012 | 4349 | 0.180 |
Why?
|
| Myasthenia Gravis | 1 | 2023 | 214 | 0.180 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2003 | 565 | 0.180 |
Why?
|
| Macrophages | 8 | 2006 | 5784 | 0.180 |
Why?
|
| Immunophenotyping | 5 | 2015 | 1867 | 0.170 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2001 | 229 | 0.170 |
Why?
|
| Myositis | 1 | 2023 | 268 | 0.170 |
Why?
|
| Hydrocarbons, Brominated | 3 | 2009 | 29 | 0.170 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2020 | 101 | 0.170 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2001 | 240 | 0.170 |
Why?
|
| Chemokine CCL22 | 3 | 2014 | 27 | 0.170 |
Why?
|
| Recombinant Proteins | 17 | 2005 | 6507 | 0.170 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2015 | 306 | 0.170 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 17089 | 0.170 |
Why?
|
| Biopsy | 7 | 2019 | 6779 | 0.170 |
Why?
|
| Anaerobiosis | 3 | 2008 | 140 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 9 | 2018 | 6225 | 0.170 |
Why?
|
| Fucosyltransferases | 2 | 2018 | 118 | 0.160 |
Why?
|
| Lectins, C-Type | 3 | 2015 | 592 | 0.160 |
Why?
|
| Periodontitis | 1 | 2004 | 576 | 0.160 |
Why?
|
| Male | 62 | 2024 | 364154 | 0.160 |
Why?
|
| Th1 Cells | 3 | 2013 | 1040 | 0.160 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 7 | 1997 | 892 | 0.160 |
Why?
|
| Chemokine CXCL12 | 1 | 2021 | 457 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 3610 | 0.160 |
Why?
|
| Scleroderma, Systemic | 3 | 2005 | 346 | 0.160 |
Why?
|
| Prognosis | 8 | 2019 | 29959 | 0.160 |
Why?
|
| Biodegradation, Environmental | 3 | 2008 | 220 | 0.150 |
Why?
|
| Dipeptidyl Peptidase 4 | 2 | 2010 | 93 | 0.150 |
Why?
|
| Integrin beta Chains | 1 | 2018 | 116 | 0.150 |
Why?
|
| Alopecia | 2 | 2000 | 416 | 0.150 |
Why?
|
| Nucleotides, Cyclic | 1 | 2019 | 83 | 0.150 |
Why?
|
| Cell Differentiation | 5 | 2017 | 11657 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 5690 | 0.150 |
Why?
|
| Switzerland | 7 | 2009 | 322 | 0.150 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2024 | 617 | 0.150 |
Why?
|
| Methotrexate | 1 | 2004 | 1719 | 0.150 |
Why?
|
| Vaccination | 3 | 2023 | 3435 | 0.150 |
Why?
|
| Deoxyribonucleases | 1 | 2019 | 209 | 0.140 |
Why?
|
| Lymphokines | 5 | 1988 | 924 | 0.140 |
Why?
|
| Lymphocyte Count | 3 | 2012 | 794 | 0.140 |
Why?
|
| Natural Killer T-Cells | 1 | 2021 | 319 | 0.140 |
Why?
|
| Interleukin-10 | 4 | 2009 | 1182 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 3 | 2011 | 1349 | 0.140 |
Why?
|
| Interleukin-6 | 7 | 2015 | 3226 | 0.140 |
Why?
|
| Apoptosis | 6 | 2017 | 9514 | 0.140 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2010 | 94 | 0.140 |
Why?
|
| Focal Dermal Hypoplasia | 1 | 2016 | 7 | 0.140 |
Why?
|
| Selectins | 1 | 1997 | 101 | 0.140 |
Why?
|
| Collagen | 4 | 1995 | 2635 | 0.140 |
Why?
|
| Pruritus | 2 | 2017 | 378 | 0.140 |
Why?
|
| Leukemia | 2 | 2016 | 1521 | 0.140 |
Why?
|
| Brachytherapy | 2 | 2016 | 1221 | 0.140 |
Why?
|
| HLA-DR Antigens | 2 | 2015 | 609 | 0.140 |
Why?
|
| Nucleotidyltransferases | 1 | 2019 | 242 | 0.140 |
Why?
|
| Skin Diseases, Infectious | 1 | 2017 | 75 | 0.140 |
Why?
|
| Mast Cells | 3 | 2012 | 1405 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2022 | 2841 | 0.140 |
Why?
|
| Receptors, Interleukin | 2 | 2012 | 243 | 0.140 |
Why?
|
| Endotoxins | 4 | 1994 | 519 | 0.130 |
Why?
|
| Cell Cycle | 3 | 2016 | 2925 | 0.130 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 156 | 0.130 |
Why?
|
| Mucins | 2 | 2022 | 569 | 0.130 |
Why?
|
| Middle Aged | 36 | 2022 | 223267 | 0.130 |
Why?
|
| Chemokines, CC | 3 | 2004 | 285 | 0.130 |
Why?
|
| Receptors, CCR6 | 2 | 2006 | 73 | 0.130 |
Why?
|
| Cell Migration Assays | 1 | 2016 | 22 | 0.130 |
Why?
|
| Disease Management | 2 | 2019 | 2533 | 0.130 |
Why?
|
| Amino Acid Sequence | 8 | 2017 | 13411 | 0.130 |
Why?
|
| Interleukin-4 | 5 | 2013 | 1156 | 0.130 |
Why?
|
| Administration, Cutaneous | 3 | 2017 | 712 | 0.130 |
Why?
|
| Foot Dermatoses | 1 | 2016 | 46 | 0.130 |
Why?
|
| Hand Dermatoses | 1 | 2016 | 61 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 5 | 2014 | 1996 | 0.130 |
Why?
|
| Erythema | 2 | 2014 | 261 | 0.130 |
Why?
|
| Agriculture | 2 | 2007 | 186 | 0.130 |
Why?
|
| Myocarditis | 1 | 2023 | 802 | 0.130 |
Why?
|
| Aged, 80 and over | 16 | 2019 | 59548 | 0.130 |
Why?
|
| Azacitidine | 1 | 2017 | 337 | 0.130 |
Why?
|
| Granzymes | 2 | 2015 | 278 | 0.120 |
Why?
|
| Cephalexin | 1 | 2015 | 37 | 0.120 |
Why?
|
| Haptens | 1 | 2015 | 163 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 183 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2017 | 3605 | 0.120 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2015 | 50 | 0.120 |
Why?
|
| Case-Control Studies | 10 | 2024 | 22248 | 0.120 |
Why?
|
| Antigens, Surface | 2 | 2013 | 1617 | 0.120 |
Why?
|
| Hamartoma | 1 | 1997 | 235 | 0.120 |
Why?
|
| Radiotherapy | 2 | 2019 | 1497 | 0.120 |
Why?
|
| Molecular Weight | 7 | 2007 | 2168 | 0.120 |
Why?
|
| Adult | 28 | 2020 | 223305 | 0.120 |
Why?
|
| Chemokines, CXC | 1 | 1996 | 420 | 0.120 |
Why?
|
| Disease Progression | 8 | 2020 | 13642 | 0.120 |
Why?
|
| Documentation | 2 | 2018 | 914 | 0.120 |
Why?
|
| Cyclophosphamide | 4 | 2004 | 2234 | 0.110 |
Why?
|
| Disease Susceptibility | 3 | 2019 | 1791 | 0.110 |
Why?
|
| Interleukin-3 | 2 | 1993 | 425 | 0.110 |
Why?
|
| STAT4 Transcription Factor | 1 | 2014 | 94 | 0.110 |
Why?
|
| Cell Survival | 3 | 2017 | 5749 | 0.110 |
Why?
|
| Oxidation-Reduction | 2 | 2017 | 2221 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2020 | 2603 | 0.110 |
Why?
|
| Leukocytes | 4 | 1997 | 2034 | 0.110 |
Why?
|
| Skin Physiological Phenomena | 3 | 1992 | 193 | 0.110 |
Why?
|
| Transcription Factors | 4 | 2012 | 12159 | 0.110 |
Why?
|
| Environmental Monitoring | 5 | 2007 | 1467 | 0.110 |
Why?
|
| Morpholines | 1 | 2017 | 584 | 0.110 |
Why?
|
| Extracellular Matrix | 2 | 1991 | 1730 | 0.110 |
Why?
|
| Immunoglobulin G | 3 | 2012 | 4559 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 4570 | 0.110 |
Why?
|
| Coculture Techniques | 4 | 2020 | 1337 | 0.110 |
Why?
|
| Piperidines | 1 | 2022 | 1663 | 0.110 |
Why?
|
| Chemotaxis | 3 | 2012 | 598 | 0.110 |
Why?
|
| Aged | 27 | 2024 | 171344 | 0.110 |
Why?
|
| Mannose-Binding Lectins | 1 | 2013 | 100 | 0.110 |
Why?
|
| Bone Diseases | 1 | 2016 | 412 | 0.110 |
Why?
|
| Suntan | 1 | 2012 | 17 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 1995 | 605 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2012 | 43 | 0.110 |
Why?
|
| Autocrine Communication | 1 | 2014 | 168 | 0.100 |
Why?
|
| Homeostasis | 5 | 2012 | 3343 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 2011 | 0.100 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2013 | 661 | 0.100 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 1994 | 262 | 0.100 |
Why?
|
| HMGB1 Protein | 1 | 2014 | 140 | 0.100 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2003 | 58 | 0.100 |
Why?
|
| Blotting, Western | 7 | 2015 | 5022 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2010 | 2931 | 0.100 |
Why?
|
| Biological Transport | 1 | 2017 | 2083 | 0.100 |
Why?
|
| Radiation Chimera | 1 | 2012 | 216 | 0.100 |
Why?
|
| Lung | 2 | 2011 | 10068 | 0.100 |
Why?
|
| Paracrine Communication | 1 | 2014 | 277 | 0.100 |
Why?
|
| Panniculitis | 1 | 2012 | 45 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2024 | 2416 | 0.100 |
Why?
|
| Molecular Sequence Data | 11 | 2012 | 17609 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 8540 | 0.100 |
Why?
|
| Clinical Enzyme Tests | 1 | 2012 | 114 | 0.100 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2012 | 106 | 0.100 |
Why?
|
| Protein Binding | 6 | 2017 | 9326 | 0.100 |
Why?
|
| Fibronectins | 3 | 1993 | 722 | 0.100 |
Why?
|
| Thymus Gland | 3 | 2005 | 1266 | 0.100 |
Why?
|
| Facial Neoplasms | 1 | 2013 | 126 | 0.100 |
Why?
|
| Leukemia, T-Cell | 1 | 2012 | 102 | 0.100 |
Why?
|
| Single-Chain Antibodies | 1 | 2012 | 114 | 0.100 |
Why?
|
| Subcutaneous Tissue | 1 | 2012 | 131 | 0.100 |
Why?
|
| Protein C | 1 | 2012 | 134 | 0.100 |
Why?
|
| Glycoproteins | 2 | 2012 | 2201 | 0.100 |
Why?
|
| Immunoglobulin Fc Fragments | 2 | 2012 | 287 | 0.100 |
Why?
|
| Diagnosis-Related Groups | 1 | 2013 | 445 | 0.090 |
Why?
|
| Vitreous Body | 1 | 1993 | 401 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 381 | 0.090 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 151 | 0.090 |
Why?
|
| Polybrominated Biphenyls | 2 | 2007 | 25 | 0.090 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2012 | 306 | 0.090 |
Why?
|
| Galectin 1 | 1 | 2012 | 128 | 0.090 |
Why?
|
| Cancer Vaccines | 2 | 2012 | 1042 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 258 | 0.090 |
Why?
|
| Receptors, Immunologic | 4 | 1990 | 1417 | 0.090 |
Why?
|
| Blood Coagulation Tests | 1 | 2012 | 269 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2012 | 163 | 0.090 |
Why?
|
| Antigenic Variation | 1 | 2011 | 117 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 4215 | 0.090 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2012 | 257 | 0.090 |
Why?
|
| Receptors, CCR10 | 1 | 2010 | 10 | 0.090 |
Why?
|
| Nevus, Halo | 1 | 2010 | 5 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 3 | 1997 | 1965 | 0.090 |
Why?
|
| Polyomavirus Infections | 1 | 2012 | 193 | 0.090 |
Why?
|
| Protein Precursors | 2 | 2011 | 1134 | 0.090 |
Why?
|
| Mice, Inbred C3H | 5 | 2015 | 915 | 0.090 |
Why?
|
| Transgenes | 3 | 2006 | 1014 | 0.090 |
Why?
|
| Dihydroxycholecalciferols | 1 | 2010 | 17 | 0.090 |
Why?
|
| Chemokine CCL21 | 1 | 2010 | 49 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2020 | 3796 | 0.090 |
Why?
|
| Cell Lineage | 3 | 2024 | 2573 | 0.090 |
Why?
|
| Cecum | 1 | 1991 | 231 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 432 | 0.090 |
Why?
|
| Macrophage-1 Antigen | 1 | 1991 | 286 | 0.090 |
Why?
|
| Cell Line | 14 | 2019 | 15564 | 0.090 |
Why?
|
| Bacterial Infections | 2 | 1991 | 1390 | 0.090 |
Why?
|
| Antigens, Differentiation | 2 | 2006 | 921 | 0.090 |
Why?
|
| Carcinogens | 2 | 2003 | 452 | 0.080 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 2429 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 1998 | 1442 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2022 | 3043 | 0.080 |
Why?
|
| DNA Primers | 4 | 2012 | 2826 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2012 | 438 | 0.080 |
Why?
|
| Melanoma, Experimental | 2 | 2012 | 557 | 0.080 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 162 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2013 | 1902 | 0.080 |
Why?
|
| Gene Expression Regulation | 7 | 2015 | 11924 | 0.080 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2015 | 551 | 0.080 |
Why?
|
| Immunohistochemistry | 8 | 2012 | 11062 | 0.080 |
Why?
|
| Trout | 1 | 2009 | 20 | 0.080 |
Why?
|
| Biological Products | 3 | 1987 | 948 | 0.080 |
Why?
|
| Mice, Inbred Strains | 4 | 2000 | 1767 | 0.080 |
Why?
|
| Oxazolone | 2 | 1999 | 61 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1996 | 1657 | 0.080 |
Why?
|
| Diphtheria Toxin | 1 | 2010 | 253 | 0.080 |
Why?
|
| Vitiligo | 1 | 2010 | 97 | 0.080 |
Why?
|
| Blood Circulation | 1 | 2010 | 248 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2017 | 3139 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 792 | 0.080 |
Why?
|
| Lymphoma | 2 | 2016 | 1899 | 0.080 |
Why?
|
| Virus Replication | 3 | 2019 | 2457 | 0.080 |
Why?
|
| Halogenated Diphenyl Ethers | 1 | 2009 | 84 | 0.080 |
Why?
|
| Signal Transduction | 7 | 2019 | 23618 | 0.080 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 715 | 0.080 |
Why?
|
| Specialization | 1 | 2013 | 779 | 0.080 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2012 | 329 | 0.080 |
Why?
|
| Edema | 1 | 2012 | 764 | 0.080 |
Why?
|
| Actins | 1 | 1995 | 2061 | 0.080 |
Why?
|
| Microcirculation | 3 | 2005 | 1282 | 0.070 |
Why?
|
| Eye Diseases | 1 | 1993 | 660 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 5 | 2015 | 6105 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 6 | 2008 | 6066 | 0.070 |
Why?
|
| Drug Eruptions | 1 | 1991 | 335 | 0.070 |
Why?
|
| Cycloheximide | 1 | 1988 | 340 | 0.070 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 903 | 0.070 |
Why?
|
| Treatment Outcome | 9 | 2022 | 65286 | 0.070 |
Why?
|
| Cicatrix | 1 | 2013 | 798 | 0.070 |
Why?
|
| Food Contamination | 1 | 2009 | 193 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2015 | 2741 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 559 | 0.070 |
Why?
|
| Genetic Testing | 2 | 2015 | 3591 | 0.070 |
Why?
|
| Waste Products | 1 | 2007 | 12 | 0.070 |
Why?
|
| Ovalbumin | 1 | 2009 | 677 | 0.070 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1991 | 833 | 0.070 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 1130 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 6514 | 0.070 |
Why?
|
| Membrane Proteins | 4 | 2019 | 7869 | 0.070 |
Why?
|
| Femoral Fractures | 1 | 1991 | 376 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2008 | 513 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 7475 | 0.070 |
Why?
|
| Proteins | 2 | 2014 | 6002 | 0.070 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2006 | 40 | 0.070 |
Why?
|
| Construction Materials | 1 | 2007 | 60 | 0.070 |
Why?
|
| Metalloendopeptidases | 2 | 2001 | 386 | 0.070 |
Why?
|
| Endothelium | 3 | 1999 | 768 | 0.070 |
Why?
|
| Chemokine CCL17 | 2 | 2004 | 26 | 0.070 |
Why?
|
| Remission Induction | 2 | 2010 | 2413 | 0.070 |
Why?
|
| Serine Endopeptidases | 1 | 1991 | 1027 | 0.070 |
Why?
|
| Lymphoid Tissue | 1 | 1988 | 445 | 0.070 |
Why?
|
| Organic Chemicals | 1 | 2007 | 211 | 0.070 |
Why?
|
| Picibanil | 1 | 2005 | 10 | 0.060 |
Why?
|
| Transduction, Genetic | 2 | 2012 | 899 | 0.060 |
Why?
|
| Base Sequence | 6 | 2017 | 12415 | 0.060 |
Why?
|
| Dermatologic Agents | 1 | 2010 | 314 | 0.060 |
Why?
|
| Clonal Deletion | 1 | 2005 | 75 | 0.060 |
Why?
|
| Patient Admission | 1 | 2013 | 1364 | 0.060 |
Why?
|
| Tretinoin | 2 | 1989 | 524 | 0.060 |
Why?
|
| Peptides | 2 | 2015 | 4347 | 0.060 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2005 | 111 | 0.060 |
Why?
|
| Leg Ulcer | 1 | 2005 | 71 | 0.060 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2006 | 199 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 947 | 0.060 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2016 | 230 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 3485 | 0.060 |
Why?
|
| Plants | 1 | 2007 | 332 | 0.060 |
Why?
|
| Wound Infection | 1 | 1987 | 244 | 0.060 |
Why?
|
| Insecticides | 1 | 2007 | 203 | 0.060 |
Why?
|
| Vaccines, Attenuated | 1 | 2006 | 314 | 0.060 |
Why?
|
| Perfume | 1 | 2004 | 9 | 0.060 |
Why?
|
| Receptors, Cytokine | 2 | 2014 | 258 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2006 | 565 | 0.060 |
Why?
|
| Self Tolerance | 1 | 2005 | 122 | 0.060 |
Why?
|
| Neutrophil Activation | 1 | 2005 | 180 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 5795 | 0.060 |
Why?
|
| Paired Box Transcription Factors | 1 | 2005 | 205 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 3803 | 0.060 |
Why?
|
| Lymphocyte Culture Test, Mixed | 5 | 2003 | 511 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 3 | 2015 | 1604 | 0.060 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2004 | 30 | 0.060 |
Why?
|
| Interphase | 2 | 2003 | 226 | 0.060 |
Why?
|
| Carcinoma | 1 | 1996 | 2325 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12064 | 0.060 |
Why?
|
| Sunscreening Agents | 1 | 2005 | 138 | 0.060 |
Why?
|
| Benzofurans | 1 | 2005 | 139 | 0.060 |
Why?
|
| Stress, Mechanical | 2 | 2001 | 1674 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 2901 | 0.060 |
Why?
|
| Adenosine Deaminase | 1 | 2006 | 253 | 0.060 |
Why?
|
| Antigen Presentation | 3 | 2003 | 1250 | 0.060 |
Why?
|
| CHO Cells | 3 | 2002 | 1376 | 0.060 |
Why?
|
| Statistical Distributions | 1 | 2004 | 60 | 0.060 |
Why?
|
| Blood | 1 | 2006 | 598 | 0.060 |
Why?
|
| Jurkat Cells | 1 | 2005 | 740 | 0.060 |
Why?
|
| Escherichia coli Proteins | 1 | 2010 | 1055 | 0.060 |
Why?
|
| Antibodies, Viral | 2 | 2012 | 3213 | 0.050 |
Why?
|
| Cell Polarity | 2 | 2020 | 637 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2008 | 1882 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2003 | 114 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2005 | 590 | 0.050 |
Why?
|
| Infant, Newborn | 5 | 2018 | 26387 | 0.050 |
Why?
|
| Dental Plaque | 1 | 2004 | 214 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2006 | 554 | 0.050 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2003 | 316 | 0.050 |
Why?
|
| Cricetinae | 3 | 2002 | 2416 | 0.050 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 214 | 0.050 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2003 | 549 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 1697 | 0.050 |
Why?
|
| Testis | 1 | 2006 | 786 | 0.050 |
Why?
|
| Wounds and Injuries | 4 | 1988 | 2513 | 0.050 |
Why?
|
| Complementarity Determining Regions | 1 | 2003 | 154 | 0.050 |
Why?
|
| Retina | 1 | 1993 | 2660 | 0.050 |
Why?
|
| Gastritis | 1 | 2004 | 199 | 0.050 |
Why?
|
| Receptors, CCR8 | 1 | 2022 | 28 | 0.050 |
Why?
|
| Models, Biological | 4 | 2010 | 9464 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2006 | 995 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2004 | 826 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2012 | 1503 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 2902 | 0.050 |
Why?
|
| Acetylglucosamine | 1 | 2003 | 188 | 0.050 |
Why?
|
| Cell Communication | 2 | 2006 | 1660 | 0.050 |
Why?
|
| Vincristine | 1 | 2004 | 1040 | 0.050 |
Why?
|
| Spleen | 6 | 1991 | 2295 | 0.050 |
Why?
|
| Ovary | 1 | 2006 | 963 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 39312 | 0.050 |
Why?
|
| Chemokines | 1 | 2006 | 963 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2003 | 702 | 0.050 |
Why?
|
| Gene Library | 1 | 2004 | 1065 | 0.050 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2012 | 1417 | 0.050 |
Why?
|
| Incidence | 2 | 2019 | 21527 | 0.050 |
Why?
|
| Retinoid X Receptors | 1 | 2001 | 91 | 0.050 |
Why?
|
| Mice, Inbred CBA | 4 | 1985 | 439 | 0.050 |
Why?
|
| Alveolar Bone Loss | 1 | 2004 | 394 | 0.050 |
Why?
|
| Neuraminidase | 1 | 2001 | 192 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 9407 | 0.050 |
Why?
|
| Reference Values | 2 | 2000 | 4914 | 0.050 |
Why?
|
| Shock, Septic | 2 | 2000 | 772 | 0.050 |
Why?
|
| Palatine Tonsil | 1 | 2001 | 193 | 0.050 |
Why?
|
| Retroviridae | 1 | 2003 | 846 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 2005 | 751 | 0.040 |
Why?
|
| Protein Isoforms | 2 | 2005 | 1716 | 0.040 |
Why?
|
| Phototherapy | 1 | 2023 | 368 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2007 | 2721 | 0.040 |
Why?
|
| Dexamethasone | 1 | 1988 | 1962 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2013 | 3618 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2005 | 1339 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2015 | 3459 | 0.040 |
Why?
|
| RNA | 2 | 2003 | 2715 | 0.040 |
Why?
|
| Water | 1 | 2006 | 1416 | 0.040 |
Why?
|
| Organ Culture Techniques | 3 | 2003 | 789 | 0.040 |
Why?
|
| Prednisone | 1 | 2004 | 1566 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2004 | 1838 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2003 | 940 | 0.040 |
Why?
|
| Genes, bcl-2 | 1 | 1999 | 119 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2012 | 4926 | 0.040 |
Why?
|
| Streptococcus pyogenes | 1 | 2022 | 293 | 0.040 |
Why?
|
| Butterflies | 1 | 2019 | 7 | 0.040 |
Why?
|
| Cell Line, Transformed | 2 | 1993 | 861 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2022 | 853 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2006 | 1610 | 0.040 |
Why?
|
| Genetic Vectors | 2 | 2012 | 3401 | 0.040 |
Why?
|
| Crosses, Genetic | 2 | 2000 | 751 | 0.040 |
Why?
|
| Sunburn | 1 | 2000 | 156 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 8045 | 0.040 |
Why?
|
| Chemokine CCL5 | 2 | 2016 | 214 | 0.040 |
Why?
|
| Immunomagnetic Separation | 1 | 1999 | 78 | 0.040 |
Why?
|
| Moths | 1 | 2019 | 81 | 0.040 |
Why?
|
| Genomics | 1 | 2015 | 5922 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2014 | 777 | 0.040 |
Why?
|
| Baculoviridae | 1 | 2019 | 115 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 54872 | 0.040 |
Why?
|
| Hemorheology | 1 | 1999 | 144 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2024 | 1080 | 0.040 |
Why?
|
| Sepsis | 2 | 1991 | 2604 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 1986 | 1838 | 0.040 |
Why?
|
| Genes, ras | 1 | 2001 | 656 | 0.040 |
Why?
|
| beta Carotene | 1 | 2000 | 523 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 1988 | 2060 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2001 | 546 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 2144 | 0.040 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 2 | 1988 | 31 | 0.040 |
Why?
|
| Second Messenger Systems | 1 | 2019 | 203 | 0.040 |
Why?
|
| Epithelium | 5 | 1992 | 1606 | 0.040 |
Why?
|
| Ear, External | 1 | 1999 | 165 | 0.040 |
Why?
|
| Foreskin | 1 | 2018 | 33 | 0.040 |
Why?
|
| Hypohidrosis | 1 | 1998 | 29 | 0.040 |
Why?
|
| Melanocytes | 2 | 2012 | 509 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2004 | 838 | 0.040 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1998 | 318 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1999 | 491 | 0.040 |
Why?
|
| Culture Media, Serum-Free | 1 | 1997 | 147 | 0.040 |
Why?
|
| Receptors, Interleukin-1 Type II | 1 | 1997 | 11 | 0.040 |
Why?
|
| Genes, Viral | 1 | 2019 | 654 | 0.040 |
Why?
|
| Immunoblotting | 2 | 1998 | 1647 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2010 | 10101 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2004 | 1126 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 2586 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2001 | 1228 | 0.030 |
Why?
|
| Kaposi Varicelliform Eruption | 1 | 2017 | 47 | 0.030 |
Why?
|
| Blood Cells | 1 | 1999 | 309 | 0.030 |
Why?
|
| Receptors, HIV | 1 | 1997 | 159 | 0.030 |
Why?
|
| Kinetics | 5 | 1998 | 6288 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2010 | 7612 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2004 | 4860 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 1998 | 1062 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2001 | 1527 | 0.030 |
Why?
|
| Transfection | 3 | 1993 | 5755 | 0.030 |
Why?
|
| Sweat Gland Neoplasms | 1 | 1998 | 111 | 0.030 |
Why?
|
| Chemokine CXCL1 | 1 | 1996 | 102 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 2730 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2006 | 2801 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2001 | 5143 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2000 | 614 | 0.030 |
Why?
|
| Integrin alpha2 | 1 | 1995 | 39 | 0.030 |
Why?
|
| Sjogren's Syndrome | 1 | 1998 | 240 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2016 | 238 | 0.030 |
Why?
|
| Substance P | 1 | 2017 | 331 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 224 | 0.030 |
Why?
|
| Chemotactic Factors | 1 | 1996 | 197 | 0.030 |
Why?
|
| Ear | 1 | 1996 | 172 | 0.030 |
Why?
|
| Cell Size | 1 | 1997 | 625 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2008 | 3582 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2019 | 1159 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2000 | 1968 | 0.030 |
Why?
|
| Environmental Pollutants | 1 | 2005 | 1292 | 0.030 |
Why?
|
| Young Adult | 6 | 2020 | 59939 | 0.030 |
Why?
|
| Immune Evasion | 1 | 2019 | 375 | 0.030 |
Why?
|
| Sialomucins | 1 | 1994 | 18 | 0.030 |
Why?
|
| Gelsolin | 1 | 1995 | 189 | 0.030 |
Why?
|
| Efferent Pathways | 1 | 1995 | 164 | 0.030 |
Why?
|
| Bone Marrow Cells | 2 | 2002 | 2413 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2024 | 81657 | 0.030 |
Why?
|
| Cell Membrane | 3 | 1997 | 3642 | 0.030 |
Why?
|
| Endonucleases | 2 | 1988 | 371 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2015 | 93 | 0.030 |
Why?
|
| Nails | 1 | 2016 | 298 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 18076 | 0.030 |
Why?
|
| Saphenous Vein | 1 | 1997 | 519 | 0.030 |
Why?
|
| Time Factors | 7 | 2018 | 40149 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 692 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 349 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2887 | 0.030 |
Why?
|
| Afferent Pathways | 1 | 1995 | 303 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2019 | 1947 | 0.030 |
Why?
|
| NADP | 1 | 2015 | 229 | 0.030 |
Why?
|
| Mites | 1 | 1994 | 46 | 0.030 |
Why?
|
| Triazines | 2 | 2007 | 311 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1994 | 848 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1995 | 1550 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 1994 | 423 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1997 | 827 | 0.030 |
Why?
|
| Autoradiography | 1 | 1994 | 725 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 361 | 0.030 |
Why?
|
| Isoantigens | 1 | 1996 | 562 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 711 | 0.030 |
Why?
|
| STAT6 Transcription Factor | 1 | 2014 | 196 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1995 | 390 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 695 | 0.030 |
Why?
|
| Depsipeptides | 1 | 2014 | 95 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1995 | 1431 | 0.030 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1993 | 205 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2015 | 415 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 3427 | 0.030 |
Why?
|
| Pigment Epithelium of Eye | 1 | 1993 | 209 | 0.030 |
Why?
|
| Hair | 1 | 2016 | 508 | 0.030 |
Why?
|
| Leukocytosis | 1 | 1994 | 249 | 0.030 |
Why?
|
| Monophenol Monooxygenase | 1 | 2012 | 72 | 0.030 |
Why?
|
| Scalp | 1 | 1995 | 390 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 2629 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 2016 | 470 | 0.030 |
Why?
|
| Glutathione | 1 | 2015 | 589 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1993 | 529 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2008 | 4747 | 0.030 |
Why?
|
| Chromogenic Compounds | 1 | 2012 | 29 | 0.030 |
Why?
|
| alpha-MSH | 1 | 2012 | 71 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 5795 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 1997 | 1562 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2000 | 1188 | 0.020 |
Why?
|
| Growth Hormone | 1 | 1994 | 572 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2005 | 4787 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2018 | 2921 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 1729 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 9613 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2019 | 2201 | 0.020 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2011 | 48 | 0.020 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 256 | 0.020 |
Why?
|
| Introns | 1 | 1994 | 966 | 0.020 |
Why?
|
| Antioxidants | 1 | 2000 | 1671 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2004 | 2286 | 0.020 |
Why?
|
| Chymases | 1 | 1991 | 84 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 1993 | 521 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2011 | 89 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2012 | 4168 | 0.020 |
Why?
|
| Adolescent | 6 | 2019 | 88902 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Melanocyte-Stimulating Hormones | 1 | 1991 | 25 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2004 | 2817 | 0.020 |
Why?
|
| Receptors, Pituitary Hormone | 1 | 1991 | 29 | 0.020 |
Why?
|
| NF-kappa B | 1 | 1999 | 2493 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2012 | 271 | 0.020 |
Why?
|
| Cytoplasm | 1 | 1995 | 1505 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2013 | 877 | 0.020 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2012 | 301 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2005 | 2930 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 483 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2012 | 645 | 0.020 |
Why?
|
| Necrosis | 1 | 2015 | 1614 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 317 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 578 | 0.020 |
Why?
|
| Immunoconjugates | 1 | 1998 | 976 | 0.020 |
Why?
|
| Melanins | 1 | 2012 | 291 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 376 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 1993 | 618 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2016 | 743 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2012 | 487 | 0.020 |
Why?
|
| Skin Transplantation | 2 | 2003 | 1097 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2011 | 261 | 0.020 |
Why?
|
| Electronic Health Records | 2 | 2018 | 4880 | 0.020 |
Why?
|
| Europe | 2 | 2007 | 3430 | 0.020 |
Why?
|
| Seasons | 2 | 2007 | 1519 | 0.020 |
Why?
|
| Research Design | 2 | 2016 | 6206 | 0.020 |
Why?
|
| Antibodies | 3 | 1993 | 2421 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2016 | 2659 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 1150 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 1993 | 1989 | 0.020 |
Why?
|
| Pigmentation | 1 | 2010 | 143 | 0.020 |
Why?
|
| HIV | 1 | 1996 | 1588 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1998 | 2115 | 0.020 |
Why?
|
| Chromatography, Gel | 2 | 1988 | 634 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 14073 | 0.020 |
Why?
|
| Thrombin | 1 | 2012 | 600 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 2012 | 738 | 0.020 |
Why?
|
| Mitogens | 1 | 1989 | 229 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 12985 | 0.020 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2009 | 129 | 0.020 |
Why?
|
| Perforin | 1 | 2009 | 167 | 0.020 |
Why?
|
| Fresh Water | 1 | 2009 | 82 | 0.020 |
Why?
|
| HIV-1 | 2 | 1997 | 6948 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2019 | 5388 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 11876 | 0.020 |
Why?
|
| Exons | 1 | 1994 | 2392 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2022 | 3833 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 657 | 0.020 |
Why?
|
| Embryonic and Fetal Development | 1 | 1989 | 420 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 1057 | 0.020 |
Why?
|
| United States | 4 | 2024 | 72945 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 1211 | 0.020 |
Why?
|
| HIV Infections | 3 | 2003 | 17532 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 751 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 384 | 0.020 |
Why?
|
| Fingers | 1 | 1991 | 508 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 614 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2270 | 0.020 |
Why?
|
| DNA Replication | 2 | 1991 | 1426 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 1993 | 2677 | 0.020 |
Why?
|
| 2-Methyl-4-chlorophenoxyacetic Acid | 1 | 2007 | 2 | 0.020 |
Why?
|
| MART-1 Antigen | 1 | 2007 | 62 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 2746 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 2177 | 0.020 |
Why?
|
| Plant Physiological Phenomena | 1 | 2007 | 16 | 0.020 |
Why?
|
| Dependovirus | 1 | 2012 | 720 | 0.020 |
Why?
|
| Isomerism | 1 | 2007 | 197 | 0.020 |
Why?
|
| Secretory Rate | 1 | 1986 | 82 | 0.020 |
Why?
|
| Water Pollution | 1 | 2007 | 31 | 0.020 |
Why?
|
| Aerobiosis | 1 | 2007 | 100 | 0.020 |
Why?
|
| Endopeptidases | 1 | 1991 | 762 | 0.020 |
Why?
|
| Proteomics | 1 | 2021 | 3915 | 0.020 |
Why?
|
| Oncogenes | 1 | 2012 | 1232 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 1751 | 0.020 |
Why?
|
| Species Specificity | 1 | 1991 | 2413 | 0.020 |
Why?
|
| Rats | 4 | 1999 | 23717 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 1741 | 0.020 |
Why?
|
| Cell Count | 2 | 2003 | 1826 | 0.020 |
Why?
|
| Body Fluids | 1 | 1988 | 321 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1988 | 1529 | 0.020 |
Why?
|
| Face | 1 | 2012 | 1029 | 0.020 |
Why?
|
| Blister | 1 | 1986 | 88 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 545 | 0.020 |
Why?
|
| Culture Media | 4 | 1990 | 893 | 0.020 |
Why?
|
| Exudates and Transudates | 1 | 1986 | 175 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1991 | 2228 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 2916 | 0.020 |
Why?
|
| Alprostadil | 1 | 2005 | 86 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1894 | 0.020 |
Why?
|
| Furans | 1 | 2007 | 199 | 0.020 |
Why?
|
| Camphor | 1 | 2005 | 9 | 0.020 |
Why?
|
| Suppressor Factors, Immunologic | 1 | 1985 | 68 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 15425 | 0.020 |
Why?
|
| Sunlight | 1 | 1987 | 336 | 0.020 |
Why?
|
| Lipopolysaccharides | 2 | 1994 | 2215 | 0.020 |
Why?
|
| Polymyositis | 1 | 2005 | 75 | 0.020 |
Why?
|
| Luminescence | 1 | 2005 | 108 | 0.020 |
Why?
|
| Medicare | 1 | 2024 | 6813 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1991 | 3053 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2547 | 0.020 |
Why?
|
| Cinnamates | 1 | 2005 | 59 | 0.020 |
Why?
|
| Acrylates | 1 | 2005 | 75 | 0.020 |
Why?
|
| Carbamates | 1 | 2007 | 191 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12826 | 0.020 |
Why?
|
| Granulocytes | 1 | 1987 | 551 | 0.020 |
Why?
|
| Aging | 1 | 2004 | 8728 | 0.020 |
Why?
|
| Genotype | 2 | 2012 | 13036 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1989 | 1757 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 1642 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 1852 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 2004 | 211 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 2004 | 150 | 0.010 |
Why?
|
| Child, Preschool | 3 | 2016 | 42577 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 3759 | 0.010 |
Why?
|
| Leukotriene B4 | 1 | 2005 | 281 | 0.010 |
Why?
|
| Benzopyrans | 1 | 2004 | 63 | 0.010 |
Why?
|
| Graft Survival | 1 | 2015 | 3904 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2823 | 0.010 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2004 | 85 | 0.010 |
Why?
|
| Mutation | 3 | 2014 | 30214 | 0.010 |
Why?
|
| DNA | 2 | 1988 | 7210 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2018 | 8728 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2005 | 655 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 4114 | 0.010 |
Why?
|
| GPI-Linked Proteins | 1 | 2005 | 472 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6214 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 1885 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 1600 | 0.010 |
Why?
|
| Benzoates | 1 | 2005 | 213 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1991 | 3948 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3113 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 1984 | 297 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 2952 | 0.010 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2003 | 23 | 0.010 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2003 | 59 | 0.010 |
Why?
|
| Osteoblasts | 1 | 1989 | 1144 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 2744 | 0.010 |
Why?
|
| Particle Size | 1 | 2007 | 1633 | 0.010 |
Why?
|
| Conservation of Natural Resources | 1 | 2005 | 209 | 0.010 |
Why?
|
| Epithelial Cells | 3 | 1990 | 3698 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2005 | 703 | 0.010 |
Why?
|
| Viral Load | 1 | 2012 | 3385 | 0.010 |
Why?
|
| Cities | 1 | 2005 | 542 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2008 | 3073 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1989 | 1791 | 0.010 |
Why?
|
| Mononuclear Phagocyte System | 1 | 1982 | 55 | 0.010 |
Why?
|
| Sheep | 1 | 1984 | 1448 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 684 | 0.010 |
Why?
|
| Fluorocarbons | 1 | 2007 | 498 | 0.010 |
Why?
|
| Interleukin-23 | 1 | 2003 | 202 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2015 | 3306 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 2007 | 862 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2004 | 880 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2008 | 3618 | 0.010 |
Why?
|
| Lymphocytes | 2 | 1986 | 2606 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 988 | 0.010 |
Why?
|
| Atrophy | 1 | 2006 | 1631 | 0.010 |
Why?
|
| Hepatitis, Animal | 1 | 2000 | 19 | 0.010 |
Why?
|
| Risk Assessment | 3 | 2007 | 24299 | 0.010 |
Why?
|
| Propionibacterium acnes | 1 | 2000 | 59 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4780 | 0.010 |
Why?
|
| Child | 4 | 2016 | 80670 | 0.010 |
Why?
|
| Feedback | 1 | 1984 | 797 | 0.010 |
Why?
|
| Recurrence | 1 | 2012 | 8507 | 0.010 |
Why?
|
| Peritonitis | 1 | 1982 | 368 | 0.010 |
Why?
|
| Thymidine | 2 | 1991 | 297 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2008 | 2391 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1992 | 1305 | 0.010 |
Why?
|
| Skin Ulcer | 1 | 2000 | 131 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10384 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1998 | 340 | 0.010 |
Why?
|
| Magnesium | 1 | 1982 | 815 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 1998 | 250 | 0.010 |
Why?
|
| Chemotactic Factors, Eosinophil | 1 | 1997 | 40 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2014 | 3789 | 0.010 |
Why?
|
| Chemokine CCL3 | 1 | 1997 | 84 | 0.010 |
Why?
|
| Chemokine CCL11 | 1 | 1997 | 128 | 0.010 |
Why?
|
| Chemokine CCL4 | 1 | 1997 | 126 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1998 | 861 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 1997 | 121 | 0.010 |
Why?
|
| Lichen Planus | 1 | 1998 | 70 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 6329 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 2198 | 0.010 |
Why?
|
| Pemphigus | 1 | 1998 | 107 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1998 | 1082 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 14653 | 0.010 |
Why?
|
| COS Cells | 1 | 1998 | 1135 | 0.010 |
Why?
|
| Pemphigoid, Bullous | 1 | 1998 | 110 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2000 | 1750 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1984 | 4853 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 6548 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 8928 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 26309 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1982 | 2001 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1987 | 3464 | 0.010 |
Why?
|
| Infant | 1 | 2016 | 36459 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 3587 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 20146 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1994 | 624 | 0.010 |
Why?
|
| Virus Integration | 1 | 1995 | 307 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2005 | 2160 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 1997 | 946 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 16044 | 0.010 |
Why?
|
| Enterotoxins | 1 | 1994 | 366 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 15912 | 0.010 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 1991 | 32 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 420 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 705 | 0.010 |
Why?
|
| Laminin | 1 | 1992 | 404 | 0.010 |
Why?
|
| Raynaud Disease | 1 | 1991 | 81 | 0.010 |
Why?
|
| Phagocytes | 2 | 1982 | 292 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2003 | 4504 | 0.010 |
Why?
|
| Ploidies | 1 | 1990 | 287 | 0.010 |
Why?
|
| Isoelectric Focusing | 1 | 1989 | 148 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 20710 | 0.000 |
Why?
|
| Transplantation, Isogeneic | 1 | 1988 | 250 | 0.000 |
Why?
|
| Peritoneal Cavity | 1 | 1988 | 135 | 0.000 |
Why?
|
| Embryo Implantation | 1 | 1989 | 272 | 0.000 |
Why?
|
| Concanavalin A | 1 | 1987 | 189 | 0.000 |
Why?
|
| Fixatives | 1 | 1987 | 90 | 0.000 |
Why?
|
| Dietary Supplements | 1 | 2000 | 3429 | 0.000 |
Why?
|
| Phytohemagglutinins | 1 | 1986 | 164 | 0.000 |
Why?
|
| Molecular Biology | 1 | 1990 | 573 | 0.000 |
Why?
|
| Rats, Inbred Lew | 1 | 1988 | 1168 | 0.000 |
Why?
|
| Liver | 1 | 1982 | 7571 | 0.000 |
Why?
|
| Indomethacin | 1 | 1986 | 323 | 0.000 |
Why?
|
| Blastocyst | 1 | 1989 | 432 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 2000 | 12430 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1989 | 2470 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1989 | 10745 | 0.000 |
Why?
|
| Fibrosis | 1 | 1991 | 2078 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1982 | 323 | 0.000 |
Why?
|
| Endometriosis | 1 | 1989 | 868 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1982 | 416 | 0.000 |
Why?
|
| Indocyanine Green | 1 | 1982 | 237 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1982 | 608 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1982 | 855 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2000 | 41706 | 0.000 |
Why?
|
| Wound Healing | 1 | 1988 | 2800 | 0.000 |
Why?
|
| Calcium | 1 | 1989 | 5783 | 0.000 |
Why?
|